Suggested remit - To appraise the clinical and cost effectiveness of ERC1671 within its marketing authorisation for treating glioblastoma in adults with disease that has progressed or recurred following treatment with radiotherapy and temozolomide
Status In progress
Process STA 2018
ID number 1623

Provisional Schedule

Committee meeting: 1 14 July 2020
Expected publication 23 September 2020

Project Team

Project lead Thomas Feist

Email enquiries


Key events during the development of the guidance:

Date Update
11 November 2019 Invitation to participate
14 October 2019 (10:00) Scoping workshop (Manchester)
19 August 2019 - 17 September 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
10 May 2019 In progress, Referred 29 April 2019

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance